First Trial of CRISPR-Edited T cells in Lung Cancer

First Trial of CRISPR-Edited T cells in Lung Cancer

The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supportin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Trends in molecular medicine 2020-08, Vol.26 (8), p.713-715
Hauptverfasser: Lacey, Simon F., Fraietta, Joseph A.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 715
container_issue 8
container_start_page 713
container_title Trends in molecular medicine
container_volume 26
creator Lacey, Simon F.
Fraietta, Joseph A.
description The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy.
doi_str_mv 10.1016/j.molmed.2020.06.001
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2413998666</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1471491420301490</els_id><sourcerecordid>2413998666</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-8f5f38333050d73d01f1249186a0f2729769033efffdf36c42fe1d4b83637ae73</originalsourceid><addsrcrecordid>eNp9kE9LxDAUxIMouK5-Aw85emlN-rpJcxGk7OrCgrJW8BZi8yJZ-mdNuoLf3i4Vj57eO8wMMz9CrjlLOePidpe2fdOiTTOWsZSJlDF-QmY8lzzJlXo7_ft5fk4uYtyNgoWUxYzAyoc40Cp409De0XK7fnneJkvrB7S0ojU2TaS-o5tD90FL09UYLsmZM03Eq987J6-rZVU-Jpunh3V5v0lqADUkhVs4KACALZiVYBl3PBsrFMIwl8lMSaEYADrnrANR55lDbvP3AgRIgxLm5GbK3Yf-84Bx0K2Px0Kmw_4QdZZzUKoQQozSfJLWoY8xoNP74FsTvjVn-shI7_TESB8ZaSb0iGC03U02HGd8eQw61h7HjdYHrAdte_9_wA9qVG5S</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2413998666</pqid></control><display><type>article</type><title>First Trial of CRISPR-Edited T cells in Lung Cancer</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Lacey, Simon F. ; Fraietta, Joseph A.</creator><creatorcontrib>Lacey, Simon F. ; Fraietta, Joseph A.</creatorcontrib><description>The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy.</description><identifier>ISSN: 1471-4914</identifier><identifier>EISSN: 1471-499X</identifier><identifier>DOI: 10.1016/j.molmed.2020.06.001</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Trends in molecular medicine, 2020-08, Vol.26 (8), p.713-715</ispartof><rights>2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-8f5f38333050d73d01f1249186a0f2729769033efffdf36c42fe1d4b83637ae73</citedby><cites>FETCH-LOGICAL-c339t-8f5f38333050d73d01f1249186a0f2729769033efffdf36c42fe1d4b83637ae73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.molmed.2020.06.001$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids></links><search><creatorcontrib>Lacey, Simon F.</creatorcontrib><creatorcontrib>Fraietta, Joseph A.</creatorcontrib><title>First Trial of CRISPR-Edited T cells in Lung Cancer</title><title>Trends in molecular medicine</title><description>The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy.</description><issn>1471-4914</issn><issn>1471-499X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE9LxDAUxIMouK5-Aw85emlN-rpJcxGk7OrCgrJW8BZi8yJZ-mdNuoLf3i4Vj57eO8wMMz9CrjlLOePidpe2fdOiTTOWsZSJlDF-QmY8lzzJlXo7_ft5fk4uYtyNgoWUxYzAyoc40Cp409De0XK7fnneJkvrB7S0ojU2TaS-o5tD90FL09UYLsmZM03Eq987J6-rZVU-Jpunh3V5v0lqADUkhVs4KACALZiVYBl3PBsrFMIwl8lMSaEYADrnrANR55lDbvP3AgRIgxLm5GbK3Yf-84Bx0K2Px0Kmw_4QdZZzUKoQQozSfJLWoY8xoNP74FsTvjVn-shI7_TESB8ZaSb0iGC03U02HGd8eQw61h7HjdYHrAdte_9_wA9qVG5S</recordid><startdate>202008</startdate><enddate>202008</enddate><creator>Lacey, Simon F.</creator><creator>Fraietta, Joseph A.</creator><general>Elsevier Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202008</creationdate><title>First Trial of CRISPR-Edited T cells in Lung Cancer</title><author>Lacey, Simon F. ; Fraietta, Joseph A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-8f5f38333050d73d01f1249186a0f2729769033efffdf36c42fe1d4b83637ae73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lacey, Simon F.</creatorcontrib><creatorcontrib>Fraietta, Joseph A.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Trends in molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lacey, Simon F.</au><au>Fraietta, Joseph A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First Trial of CRISPR-Edited T cells in Lung Cancer</atitle><jtitle>Trends in molecular medicine</jtitle><date>2020-08</date><risdate>2020</risdate><volume>26</volume><issue>8</issue><spage>713</spage><epage>715</epage><pages>713-715</pages><issn>1471-4914</issn><eissn>1471-499X</eissn><abstract>The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.molmed.2020.06.001</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1471-4914
ispartof Trends in molecular medicine, 2020-08, Vol.26 (8), p.713-715
issn 1471-4914
1471-499X
language eng
recordid cdi_proquest_miscellaneous_2413998666
source ScienceDirect Journals (5 years ago - present)
title First Trial of CRISPR-Edited T cells in Lung Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T05%3A20%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First%20Trial%20of%20CRISPR-Edited%20T%20cells%20in%20Lung%20Cancer&rft.jtitle=Trends%20in%20molecular%20medicine&rft.au=Lacey,%20Simon%20F.&rft.date=2020-08&rft.volume=26&rft.issue=8&rft.spage=713&rft.epage=715&rft.pages=713-715&rft.issn=1471-4914&rft.eissn=1471-499X&rft_id=info:doi/10.1016/j.molmed.2020.06.001&rft_dat=%3Cproquest_cross%3E2413998666%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2413998666&rft_id=info:pmid/&rft_els_id=S1471491420301490&rfr_iscdi=true